Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
Regenxbio could be a gene therapy pioneer with multiple ways to win in 2023
02:41pm, Friday, 02'nd Jun 2023
Regenxbio (NASDAQ:RGNX) Inc has one of the most-broad based approaches to adeno-associated virus (AAV)-based gene therapy (GT), utilizing their intellectual property (IP) to develop proprietary in-hou
REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference
07:05am, Thursday, 01'st Jun 2023
ROCKVILLE, Md. , June 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present and host one-on-one investor meetings at the Jefferies Global Healthcare Conference on
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Monday, 08'th May 2023
ROCKVILLE, Md. , May 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: BofA Securities 2023 Health Care Conferen
Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?
08:20am, Saturday, 15'th Apr 2023
RegenxBio has several collaborations with other pharmaceutical companies. The company doesn't have its own wholly owned product but receives plenty of royalty revenue.
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Wednesday, 08'th Mar 2023
ROCKVILLE, Md. , March 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Barclays Global Healthcare Conference F
REGENXBIO Inc. (RGNX) Q4 2022 Earnings Call Transcript
10:36pm, Tuesday, 28'th Feb 2023
REGENXBIO Inc. (NASDAQ:RGNX ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - Chief Executive Officer Steve Pakol
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
09:50pm, Tuesday, 28'th Feb 2023
Regenxbio (RGNX) delivered earnings and revenue surprises of 6.76% and 12.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio's Vector Technology Will Change Gene Therapy
10:15am, Wednesday, 22'nd Feb 2023
Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on
ROCKVILLE, Md. , Feb. 21, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 28, 2023, at 4:30 p.m.
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Tuesday, 22'nd Nov 2022
ROCKVILLE, Md. , Nov. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Piper Sandler 34th Annual Healthcare C
Regenxbio: Great R&D, Lack Of Near-Term Catalysts
04:17am, Monday, 21'st Nov 2022
REGENXBIO is doing important R&D for gene therapies for the eye. The stock is down due to a lack of near-term catalysts and little revenue.
REGENXBIO Inc. (RGNX) Q3 2022 Earnings Call Transcript
03:23pm, Thursday, 03'rd Nov 2022
REGENXBIO Inc. (NASDAQ:RGNX ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Patrick Christmas - Chief Legal Officer Vit Vasista - Chief Financial Officer Ken Mills
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Wednesday, 02'nd Nov 2022
ROCKVILLE, Md. , Nov. 2, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Credit Suisse 31st Annual Healthcare Co
ROCKVILLE, Md. , Oct. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the ALTITUDE® clinical trial evaluating RGX-314 using suprachoroidal deliv
What's a Fun-Sized Stock? Around $1 Billion
10:50am, Monday, 24'th Oct 2022
A company with a market value of about $1 billion is small enough to grow fast, yet large enough so that it can begin to appeal to institutional investors such as pension funds.
